

## **KURZPROTOKOLL** **I4T-MC-JVDE**

<b>Öffentlicher Titel</b>	Phase III Studie zu Ramucirumab in zweiter Linie nach Sorafenib-Behandlung bei Hepatokarzinom
<b>Wissenschaftl. Titel</b>	Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
<b>Kurztitel</b>	I4T-MC-JVDE
<b>Studienart</b>	multizentrisch, prospektiv, Therapiestudie, randomisiert, doppelblind, zweiarmig
<b>Studienphase</b>	Phase III
<b>Erkrankung</b>	Verdauung: Leberkrebs (Hepatozelluläres Karzinom): Zweitlinie oder höher
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- A diagnosis of HCC based on histopathologic findings, or a diagnosis of cirrhosis and a tumor with classical HCC imaging characteristics.</li><li>- Prior sorafenib treatment for at least 14 days and discontinuation of sorafenib 14 days prior to randomization.</li><li>- Radiographic disease progression during or after sorafenib therapy or discontinuation of sorafenib because of intolerance.</li><li>- Sorafenib was the only systemic therapy for HCC.</li><li>- 1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 that has not been previously treated with locoregional therapy. A participant with a lesion(s) that has previously been treated with locoregional therapy is also eligible, if the lesion has documented progression after locoregional treatment and is measurable.</li><li>- Child-Pugh score &lt;7 (Child-Pugh Class A).</li><li>- Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy.</li><li>- Baseline AFP 400 nanograms/milliliter.</li><li>- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.</li><li>- Resolution of all clinically significant toxic effects of prior therapy.</li><li>- Total bilirubin 1.5 times upper limit of normal value (ULN), aspartate transaminase (AST) and alanine transaminase (ALT) 5 × ULN.</li><li>- Surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method.</li><li>- If a woman of childbearing potential, a negative serum pregnancy test prior to randomization.</li><li>- Willing to provide blood for research.</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.</li><li>- Concurrent malignancy. Participants with carcinoma in situ of any origin and participants with prior malignancies in remission may be eligible with sponsor approval.</li><li>- Previous brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.</li><li>- History of or current hepatic encephalopathy or clinically meaningful ascites.</li><li>- Ongoing or recent hepatorenal syndrome.</li><li>- Liver transplant.</li><li>- Previous systemic therapy with vascular endothelial growth factor (VEGF) pathway inhibitors other than sorafenib for treatment of HCC.</li><li>- Hepatic locoregional therapy following sorafenib or within 28 days prior to randomization.</li></ul>

## **KURZPROTOKOLL I4T-MC-JVDE**

- Major surgical procedure, traumatic injury, non-healing wound, or peptic ulcer 28 days prior to randomization.
- Placement of a subcutaneous venous access device within 7 days prior to the first dose of study treatment unless the procedure is judged of low risk of bleeding.
- Enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or in medical research judged not to be scientifically or medically compatible with this study.
- Discontinued from study treatment from another clinical trial within 28 days prior to randomization.
- Known allergy to any of the treatment components.
- Uncontrolled hypertension.
- Any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, <6 months prior to randomization.
- Esophageal or gastric varices that require intervention or represent high bleeding risk. Participants with evidence of portal hypertension or prior bleeding must have had endoscopic evaluation within 3 months prior to randomization.
- Gastrointestinal perforation or fistulae within 6 months prior to randomization.
- Symptomatic congestive heart failure (New York Heart Association II-IV), unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia.
- Pregnant or breast-feeding.
- Any medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. Conditions include but are not limited to:
  - o Human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
  - o Active or uncontrolled clinically serious infection. (Participants with chronic viral hepatitis are eligible.)
  - o Ongoing or recent history of drug abuse.
  - o Uncontrolled hereditary or acquired thrombotic or bleeding disorder.
- Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection
- Therapeutic dose anticoagulation with warfarin, low molecular-weight heparin, or similar agents.
- Chronic therapy with nonsteroidal anti-inflammatory agents or other anti-platelet agents. Aspirin at doses up to 100 milligrams/day is permitted.

**Alter** 18 Jahre und älter  
**Fallzahl** 399  
**Prüfzentren** **Innere Medizin 1 (Geschlossen)**  
Gastroenterologie / Hepatologie  
Theodor-Stern-Kai 7  
60590 Frankfurt am Main  
Dr. Silke Flebbe  
Tel: 069 6301-87769  
Fax: 069 6301-6580  
[flebbe@med.uni-frankfurt.de](mailto:flebbe@med.uni-frankfurt.de)

**KURZPROTOKOLL**  
**I4T-MC-JVDE**

**Universitätsklinikum Frankfurt (Geschlossen)**  
Medizinische Klinik I, Gastroenterologie/Hepatology  
Theodor-Stern-Kai 7  
60590 Frankfurt am Main  
Dr. Silke Flebbe  
Tel: 069 6301-87769  
Fax: 069 6301-6580  
[flebbe@med.uni-frankfurt.de](mailto:flebbe@med.uni-frankfurt.de)

**Sponsor**

Eli Lilly and Company

**Förderer**

Eli Lilly and Company

**Registrierung in anderen  
Studienregistern**

ClinicalTrials.gov NCT02435433  
EudraCT 2014-005068-13